newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

  • Praxis Precision Medicines & Remagine Labs announced a research collaboration & license agreement to develop an iontophoretic transdermal patch for ulixacaltamide.
  • Praxis made an equity investment in Remagine Labs to accelerate the joint development program.
  • The transdermal patch aims to deliver ulixacaltamide via an active route, expanding the addressable market beyond the initial oral patient population.
  • Ulixacaltamide is Praxis's lead asset for essential tremor (ET) & the FDA accepted its New Drug Application in April 2026.
  • The Prescription Drug User Fee Act target action date for ulixacaltamide is set for January 29, 2027.
  • Ulixacaltamide received Breakthrough Therapy Designation in December 2025 based on the Essential3 Phase 3 program.
  • The collaboration seeks to complement the existing oral program with a programmable transdermal delivery option to strengthen competitive positioning.
  • Essential tremor affects approximately seven million people in the United States with very limited therapeutic options.